News

  Cytel announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.

Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.  

 Cytel announced the launch of OK GO, the first commercially available software to underpin quantitative go/no-go decision-making frameworks in clinical trials.  The innovative product helps sponsors make faster, more robust decisions about their products to improve their R&D productivity.  OK GO is the commercial release of custom software originally developed as a collaboration between AstraZeneca and Cytel scientists to enhance the established decision-making framework in AstraZeneca’s early clinical development group.

 Cytel Inc., a global provider of advanced analytical solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the launch of East® version 6.5, further enhancing the most trusted technology platform for designing, monitoring, and simulating adaptive trials.  Since 1995, East has empowered trial sponsors of all sizes to optimize study planning and monitoring efforts, accelerate timelines, and increase their probability of success in clinical development.

 Cytel Inc., a global provider of innovative analytical software and services to the biopharmaceutical industry, today announces the release of version 2.0 of its EnForeSys software. The upgraded version unveils expanded functionality that allows users improved interactivity and the ability to generate even more granular forecasts for resolving their feasibility challenges.

 

Cytel is confirmed as a finalist in Most Innovative Trial Design and Clinical Partnership of the Year categories at the Informa Clinical and Research Excellence Awards. The awards recognize innovation and excellence in the biopharma industry and Cytel is commended for its outsourcing partnership with Biogen and a innovative trial design created for sponsor Nestlé Health Science. The winners will be announced in April at an awards ceremony in Boston.

Congratulations to Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by the European Union’s Horizon 2020 program. Led by Lipopharma, the multinational consortium brings together 12 academic and industry organizations from Europe, Israel, and the USA.

Cytel collaborated with Lipopharma and the consortium to create the innovative trial design and provided statistical input for the successful grant application.

We mourn the loss of Sarah Fuller who passed away on October 29, 2017, at the age of 68. Ms. Fuller served as an instrumental and respected member of Cytel’s board of directors for over 10 years. An influential figure in the pharmaceutical information services sector, Ms. Fuller was the co-founder of Decision Resources Inc., a leading research and advisory firm.  Ms. Fuller also served as Executive Chairman of Millennium Prevention Inc., as a board director of The Forbes Consulting Group, and continued to act as President Emeritus of Decision Resources. Through her work as Chairman and a director, she was also a generous contributor to the work of Cultural Survival, a non-profit organization that promotes the vision, rights and voice of indigenous people. Her varied and impressive career made her an inspiration to many people. 

 Ranganath Nayak, CEO of Cytel; Cyrus Mehta, President and Co-Founder of Cytel; Nitin Patel, Chief Technical Officer and Co-Founder of Cytel; and Per Lofberg, President of Caremark Pharmacy Services share their tributes to Sarah.  To read them click the button below.

Cytel today announced further expansion in Europe with the addition of an office in Basel, Switzerland. The new premises are scheduled to open by the end of 2017 and will join the company’s existing Geneva, Paris, Barcelona, and UK locations in Europe as part of a portfolio of fifteen offices worldwide. 

Cytel is confirmed as a finalist in Most Innovative Trial Design and Best Sponsor-focused Technological Development categories at the Informa Clinical and Research Excellence Awards. The awards recognize innovation and excellence in the biopharma industry and Cytel is recognized for developments on East 6.4 and a innovative trial design created for sponsor Tracon Pharmaceuticals. The winners will be announced in April. 

Cytel announces the successful implementation of a software interface for go/no-go decision-making within its client AstraZeneca. The software is the result of extensive collaborative work by the two organizations and marks a significant advancement in quantitative decision-making capabilities for the biopharmaceutical industry.

Cytel announces the expansion of its presence in Europe with new offices in Barcelona and Paris. The new sites will enable Cytel to continue to grow its global team of biostatisticians and statistical programmers to support biopharmaceutical customers. The Barcelona location will also serve as a hub for Cytel’s fast-growing data science group. Read the full press release below.

Cytel co-founders Nitin Patel and Cyrus Mehta discuss the history of Cytel in an exclusive interview with Chance magazine.  Find out how it all began and read the article in full via the button below. 

Cytel is revealed as one of the 2016 finalists at the Scrip Awards.  The awards celebrate innovation and excellence in the pharmaceutical and biotechnology industry and will take place in London in November. The selection serves as recognition of our team's commitment to innovation and providing solutions for clinical development problems. 

Following the publication of their review article Adaptive Designs for Clinical Trials in the New England Journal of Medicine, co-authors Cyrus Mehta and Deepak L. Bhatt were invited to participate in a live video discussion with the journal covering the key features of adaptive trial designs.  To date, the video has received nearly 90,000 views, and may be accessed by clicking the link below. 

Cytel highlighted its continued success in delivering high-quality products and outsourcing solutions to the biopharmaceutical industry at the Annual Meeting of the Drug Information Association (DIA) June 26th- 30th 2016 in Philadelphia. Cytel, the world’s largest biometrics CRO and recognized leader in adaptive trial design, supported over 250 clinical research projects in 2015. This includes the addition of further functional partnerships in statistics and statistical programming to its portfolio.

Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.

Cytel delivered statistical design, analysis and reporting services for the Phase 3 double-blind placebo-controlled, active-comparator trial.

On April 7th 2016, industry publication Biospace reported on our evolution from a niche provider to a global biometrics CRO and leading software company. The article highlights examples of recent work which have led to regulatory approvals for our customers.  With plans for continued expansion, Yannis Jemiai, VP Cytel Consulting, Software Solutions and Marketing commented that "We anticipate growing by about 40 percent this year. It’s a pretty exciting time. We like to focus on and deliver quality."

The East User Group Meeting successfully brought together trial design and statistics innovators from industry and academia. Participants also gained practical experience with the new functionality of upcoming East 6.4 which was previewed at the event.  View videos of the presentations by clicking below. 

Cyrus Mehta, Cytel president and co-founder, co-authored new paper on emerging Efficacy-to-Effectiveness trials in Nature's Clinical Pharmacology & Therapeutics.  Cyrus is a noted author on the subject of successfully implementing clinical trial methodology innovations.

Raptor Pharmaceuticals CMO Patrice Rioux reveals how Cytel’s adaptive trial design and biometrics services played a pivotal role in the fast approval of Raptor's PROCYSBI. Despite issuance of an FDA SPA, the resultant adaptive trial design, medical writing and data handling plan assured their submission was thoroughly primed for approval.

Cytel friends and family continue to find inspiration in the memory of Professor Marvin Zelen. Marvin was an historic biostatistician, inspiring mentor and beloved friend of the Harvard School of Public Health community.  Marvin served on Cytel's Board of Directors from its inception.